Another study in patients with focal segmental glomerulosclerosis (FSGS) demonstrated activation of the JAK/STAT pathway as a marker of renal disease progression, suggesting this pathway might be affected by drug treatment in patients with FSGS (Tao et al. 2018). This evidence concerns the gene SOAT1 and focal segmental glomerulosclerosis.